Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection (Neptuno)

  • End date
    Dec 29, 2022
  • participants needed
  • sponsor
Updated on 29 May 2022


Treatment of patients hospitalised for management of moderate COVID-19 infection


This is a multicentre, open-label, controlled Phase 3 study in which adults requiring hospital admission and O2 supplementation for management of moderate COVID-19 infection will be randomised in 1:1:1 to: Plitidepsin 1.5 mg arm, Plitidepsin 2.5 mg arm and Control arm

Condition COVID-19 Infection
Treatment Dexamethasone, Plitidepsin, Favipiravir, Remdesivir
Clinical Study IdentifierNCT04784559
Last Modified on29 May 2022


Yes No Not Sure

Inclusion Criteria

Signed informed consent obtained prior to initiation of any study-specific procedures and study treatment
Documented diagnosis of SARS-CoV-2 infection, determined by either qualitative polymerase chain reaction (PCR) or antigen test by local laboratory, from oro nasopharyngeal exudate collected no more than 72 hours prior to study treatment on Day 1
Patient meets category 5 on the 11-point WHO Clinical Progression Scale: requires hospitalization and oxygen by mask or nasal prongs/cannula
A maximum of 10 days from onset of COVID-19 symptoms to initiation of study treatment on Day 1
Male or female aged ≥18 years
Absolute neutrophil count ≥1000/mm^3 (1.0 x 10^9/L)
Lymphocyte count ≥500/mm^3 (0.5 x 10^9/L)
Platelet count ≥100 000/mm^3 (100 x 10^9/L)
Adequate bone marrow, liver, kidney, and metabolic function, defined by the following tests performed at local laboratory
Alanine transaminase (ALT), aspartate transaminase (AST) ≤3 x upper limit of normal (ULN)
Serum bilirubin ≤1 x ULN
Calculated creatinine clearance ≥30 mL/min (Cockcroft and Gault formula)
Haemoglobin >9.0 g/dL
Creatine phosphokinase ≤2.5 x ULN except if the patient has had recent (ie, in the last week) shivering episodes or trauma. In that case, the level of creatine phosphokinase (CPK) should be ≤5 x ULN)
Females of reproductive capacity must have a negative serum or urine pregnancy test by local laboratory at study enrolment and must be non-lactating
Females and males with partners of child-bearing potential must use effective contraception while on study treatment and for 6 months after last dose of plitidepsin. Patients in the control arm must use effective contraception at the time indicated in the approved product information (summary of product characteristics [SmPC] or leaflet). If no information is available in the approved product information, patients in the control arm must use effective contraception for at least one week after the study completion or the time indicated based on the investigator's discretion
Agree not to participate in another interventional clinical trial through Day 31

Exclusion Criteria

Subjects with a pre-baseline (ie, in the prior month) impairment in general health condition for whatever reason except COVID 19, requiring either assistance for daily living activities (Barthel index <90/100) or chronic oxygen therapy
Having received treatment for COVID 19 in another clinical trial in the prior 4 weeks, except documented allocation in a placebo arm
Evidence of respiratory failure at the time of randomisation, based on resource utilisation requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (ie, clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation)
Patients with severe COVID 19, meeting score >5 on the 11 point WHO Clinical Progression Scale or presenting during the screening any of clinical signs indicative of severe systemic illness, such as respiratory rate ≥30 per minute, heart rate ≥125 per minute, or PaO2/FiO2 <300
Patients receiving treatment with antiviral therapy against SARS-CoV-2 (either small molecules or antibodies, convalescent plasma, monoclonal antibodies, IL 6 receptor inhibitor, or immunomodulatory drugs) within 2 weeks before enrolment. Prior administration of dexamethasone or equivalent glucocorticoid might be acceptable if
The total daily dose is not higher than 6 mg of dexamethasone base (equivalent to dexamethasone phosphate 7.2 mg/day) or equivalent glucocorticoid
The duration of the treatment does not exceed 72 hours prior to study treatment Day 1
History of live vaccination within the last 4 weeks prior to study enrolment
Regulatory approved, nonreplicative viral vector based vaccines are allowed if
given not earlier than 1 week previous to Day 1
Patients receiving treatment with strong cytochrome P450 3A4 ( CYP3A4) inhibitors or inducers
Viral illness (other than COVID 19) requiring therapy, except for patients with treated and adequately controlled (undetectable) human immunodeficiency virus infection
Patients receiving treatment with chloroquine or derivatives within 8 weeks before enrolment or during the study
Patients with uncontrolled known primary or secondary immunodeficiency, including chronic treatment with glucocorticoids (ie, prednisone at a daily dose of >10 mg for >1 month, or other glucocorticoid at equipotent dose)
Any of the following cardiac conditions or risk factors
Sinus bradycardia (<50 beats/min), sinus nodal dysfunction (sick sinus disease), atrioventricular block of any degree (PR >200 msec), or any other bradyarrhythmia (<50 beats/min), except for patients with permanent pacemakers
Cardiac infarction, cardiac surgery or cardiac insufficiency episode within the last 6 months
Known abnormal value of left ventricular ejection fraction (LVEF < LLN), unless documented confirmation of recovery (LVEF > LLN) in the previous month
QT interval corrected using Fridericia's formula (QTcF) >450 msec for males or >470 msec for females, based on triplicate 12-lead ECG at screening
Uncorrected hypokalaemia, hypocalcaemia (adjusted), and/or hypomagnesemia at screening
History of known congenital or acquired QT prolongation
Concomitant treatments with drugs known to be associated with a risk of QT prolongation or cardiac arrhythmia
Troponin test performed at local laboratory > 1.5 x ULN
Females who are pregnant (negative serum or urine pregnancy test required for all females of child-bearing potential at screening) or breast feeding
Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol)
Pre-existing neuropathies of any type Grade ≥2 according to National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Females and males with partners of child-bearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhoea for >12 months) who are not using at least 1 protocol-specified method of contraception
Any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardise the safety of the patient or potentially impact patient compliance or the safety/efficacy observations in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note